ABEO - Abeona Therapeutics Inc Stock Price, Fair Value and News

5.09USD+0.06 (+1.19%)Market Closed

Market Summary

USD5.09+0.06

Market Closed

1.19%

ABEO Alerts

2 major insider sales recently.

ABEO Stock Price

View Fullscreen

ABEO RSI Chart

ABEO Valuation

Market Cap

209.6M

Price/Earnings (Trailing)

-2.73

Price/Sales (Trailing)

63.54

Price/Free Cashflow

-5.16

ABEO Price/Sales (Trailing)

ABEO Profitability

Return on Equity

863.18%

Return on Assets

-102.45%

Free Cashflow Yield

-19.39%

ABEO Fundamentals

ABEO Revenue

Revenue (TTM)

3.5M

Rev. Growth (Yr)

-100%

ABEO Earnings

Earnings (TTM)

-76.7M

Earnings Growth (Yr)

-246.74%

Earnings Growth (Qtr)

-90.33%

Breaking Down ABEO Revenue

Last 7 days

0.2%

Last 30 days

19.7%

Last 90 days

54.9%

Trailing 12 Months

46.0%

How does ABEO drawdown profile look like?

ABEO Financial Health

Current Ratio

5.61

Debt/Equity

-2.04

Debt/Cashflow

-2.2

ABEO Investor Care

Shares Dilution (1Y)

119.33%

Diluted EPS (TTM)

-2.25

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	1.9M	2.5M	3.0M	3.5M
2022	1.7M	1.6M	1.5M	1.4M
2021	0	0	0	1.8M
2020	0	0	10.0M	12.2M
2018	6.9M	7.5M	9.0M	9.3M
2017	1.0M	843.0K	878.0K	837.0K
2016	1.3M	1.4M	1.5M	1.1M
2015	358.9K	672.8K	986.6K	1.3M
2014	1.0M	806.0K	853.0K	45.0K
2013	3.8M	3.6M	2.9M	2.0M
2012	3.5M	4.1M	3.9M	4.4M
2011	2.0M	1.9M	1.9M	1.8M
2010	0	0	0	2.0M

Get all data in R, Python etc through our Historical Stock Data APIs

About Abeona Therapeutics Inc

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in New York, New York.

CEO	Dr. Vishwas Seshadri M.B.A., Ph.D.
WEBSITE	abeonatherapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	57

Abeona Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Abeona Therapeutics Inc? What does ABEO stand for in stocks?

ABEO is the stock ticker symbol of Abeona Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Abeona Therapeutics Inc (ABEO)?

As of Thu Jul 25 2024, market cap of Abeona Therapeutics Inc is 207.17 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ABEO stock?

You can check ABEO's fair value in chart for subscribers.

Is Abeona Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether ABEO is over valued or under valued. Whether Abeona Therapeutics Inc is cheap or expensive depends on the assumptions which impact Abeona Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ABEO.

What is Abeona Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jul 25 2024, ABEO's PE ratio (Price to Earnings) is -2.7 and Price to Sales (PS) ratio is 63.54. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ABEO PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Abeona Therapeutics Inc's stock?

In the past 10 years, Abeona Therapeutics Inc has provided -0.1 (multiply by 100 for percentage) rate of return.